TRIO-863

N/A

Report date: 2026/05/27 17:57:53

First In Class

Base Information

Drug NameTRIO-863

Drug Alias NameTRIO-863TRIO863

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-Myeloid cell surface antigen CD33TNF-related apoptosis-inducing ligand receptors modulators

TargetsMyeloid cell surface antigen CD33TNF-related apoptosis-inducing ligand receptors

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesTRIO Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesTRIO Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A